BOCH
CMPX icon

Blue Owl Capital Holdings’s Compass Therapeutics CMPX Stock Holding History

Blue Owl Capital Holdings’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500K Buy
+400,000
New +$2.31M 0.13% 42

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Blue Owl Capital Holdings's CMPX Position: Q1 2026 in Review

Blue Owl Capital Holdings reduced its Compass Therapeutics (CMPX) stake by 15% in Q1 2026, selling an estimated $3.03M and leaving 2,941,525 shares worth $15.6M. The position accounts for 4.18% of the portfolio, ranked #8.

Blue Owl Capital Holdings first reported a position in CMPX in Q4 2023 and has held it in 10 quarters since. The position peaked at $18.6M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Blue Owl Capital Holdings held 2,941,525 shares of Compass Therapeutics worth $15.6M as of Q1 2026.
  • Blue Owl Capital Holdings sold 525,000 Compass Therapeutics shares in Q1 2026, an estimated $3.03M.
  • Compass Therapeutics made up 4.18% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #8 holding.
  • Blue Owl Capital Holdings first reported a position in Compass Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Blue Owl Capital Holdings's Compass Therapeutics position peaked at $18.6M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.